Several other analysts also recently weighed in on the company. Cantor Fitzgerald downgraded Emergent BioSolutions from an “overweight” rating to a “neutral” rating in a research note on Friday, April 29th. Zacks Investment Research upgraded Emergent BioSolutions from a “strong sell” rating to a “hold” rating and set a $45.00 target price for the company in a research note on Friday, February 18th. Cowen decreased their target price on Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Chardan Capital decreased their target price on Emergent BioSolutions from $75.00 to $65.00 in a research note on Friday, April 29th. Finally, Cowen decreased their target price on Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $48.57.
Shares of NYSE EBS opened at $31.47 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.81 and a current ratio of 4.42. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 10.81 and a beta of 0.98. The business’s 50-day simple moving average is $40.04 and its 200-day simple moving average is $42.92. Emergent BioSolutions has a 52 week low of $29.88 and a 52 week high of $68.03.
Hedge funds have recently made changes to their positions in the business. Eaton Vance Management lifted its position in shares of Emergent BioSolutions by 39.8% in the 4th quarter. Eaton Vance Management now owns 2,745 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 782 shares during the period. Cutler Group LP raised its holdings in shares of Emergent BioSolutions by 250.0% in the 1st quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 500 shares in the last quarter. Covestor Ltd acquired a new position in shares of Emergent BioSolutions in the 4th quarter worth approximately $49,000. Schroder Investment Management Group acquired a new position in shares of Emergent BioSolutions in the 4th quarter worth approximately $54,000. Finally, First Bank & Trust raised its holdings in shares of Emergent BioSolutions by 32.3% in the 4th quarter. First Bank & Trust now owns 1,850 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 452 shares in the last quarter. Institutional investors own 86.02% of the company’s stock.
Emergent BioSolutions Company Profile (Get Rating)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Peak Growth Is Over For Etsy
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.